Original Article
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
N Engl J Med 2000; 343:1290-1297November 2, 2000
- Abstract
Background
Opioid dependence is a chronic, relapsing disorder with important public health implications.
Methods
In a 17-week randomized study of 220 patients, we compared levomethadyl acetate (75 to 115 mg), buprenorphine (16 to 32 mg), and high-dose (60 to 100 mg) and low-dose (20 mg) methadone as treatments for opioid dependence. Levomethadyl acetate and buprenorphine were administered three times a week. Methadone was administered daily. Doses were individualized except in the group assigned to low-dose methadone. Patients with poor responses to treatment were switched to methadone.
Results
There were 55 patients in each group; 51 percent completed the trial. The mean (±SE) number of days that a patient remained in the study was significantly higher for those receiving levomethadyl acetate (89±6), buprenorphine (96±4), and high-dose methadone (105±4) than for those receiving low-dose methadone (70±4, P<0.001). Continued participation in the study was also significantly more frequent among patients receiving high-dose methadone than among those receiving levomethadyl acetate (P=0.02). The percentage of patients with 12 or more consecutive opioid-negative urine specimens was 36 percent in the levomethadyl acetate group, 26 percent in the buprenorphine group, 28 percent in the high-dose methadone group, and 8 percent in the low-dose methadone group (P=0.005). At the time of their last report, patients reported on a scale of 0 to 100 that their drug problem had a mean severity of 35 with levomethadyl acetate, 34 with buprenorphine, 38 with high-dose methadone, and 53 with low-dose methadone (P=0.002).
Conclusions
As compared with low-dose methadone, levomethadyl acetate, buprenorphine, and high-dose methadone substantially reduce the use of illicit opioids.
Media in This Article
Figure 1
Stages of the Trial.Figure 2
Results over the Course of the Trial.Article Activity
- Article
Opioid dependence is an important national health problem, with an estimated 980,000 long-term users of heroin in the United States.1 Methadone, introduced in the late 1960s,2 and levomethadyl acetate, approved in 1993, are two full μ-opioid agonist substitutes. Buprenorphine, a partial μ-opioid agonist (whose maximal effects are less than that of a full agonist) is under review by the Food and Drug Administration as a third pharmacotherapy for opioid dependence.3,4 Controlled studies of methadone,5-11 levomethadyl acetate,12,13 and buprenorphine14,15 have documented their dose-related efficacy in terms of retaining patients in treatment and reducing illicit opioid use.
A clinical advantage of levomethadyl acetate and buprenorphine is the option of less-than-daily doses, which is made possible in the case of levomethadyl acetate by the long half-lives of its two active metabolites, nor-levomethadyl acetate and dinor-levomethadyl acetate. Similarly, clinical pharmacologic studies16,17 and controlled trials18-21 have supported the feasibility of less-than-daily doses of buprenorphine.
Several controlled trials have compared the efficacy of levomethadyl acetate22-26 or buprenorphine11,14,27-29 with that of methadone. We compared levomethadyl acetate, buprenorphine, and methadone as treatments for opioid dependence.
Methods
Subjects and Randomization
Two hundred twenty patients participated in this single-site, randomized, controlled study with four treatment groups (Figure 1Figure 1
Stages of the Trial.). The eligibility criteria were an age of 21 to 55 years, a diagnosis of opioid dependence according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV),30 evidence of recent opioid use on toxicologic screening, the absence of serious medical or psychiatric illness requiring long-term medication, and negative results on a serum pregnancy test for women during screening. The study was approved by the local institutional review board, and all patients provided written informed consent.Patients were enrolled between January 17, 1996, and November 24, 1997. They were stratified according to the following variables: age (under 35 years or at least 35 years old), race (white or other), sex, current cocaine use (yes or no), marital status (currently married or other), and DSM-IV diagnosis of antisocial personality disorder (yes or no). They were randomly assigned to one of four treatment groups comprising 55 patients each: levomethadyl acetate (Orlaam, Roxane), buprenorphine (Reckitt and Colman), and high-dose or low-dose methadone (Methadose, Mallinckrodt). Each stratum was divided into groups of four, and a random-number generator assigned the order of the four conditions in each stratum. To correct imbalances in treatment assignment due to incomplete blocks and to increase the statistical power of the study, randomization of the last 10 patients was constrained to achieve equal numbers of patients for each treatment.31
Treatment Groups
Randomization occurred on the day of enrollment. The patients and clinic staff were unaware of treatment assignments and medication doses. The low-dose methadone group (the control group) received a fixed dose of 20 mg of methadone. However, the doses of levomethadyl acetate, buprenorphine, and high-dose methadone were adjusted within prespecified ranges to ensure that comparisons between drugs were based on individually optimized doses.
Levomethadyl Acetate
Levomethadyl acetate was administered at a dose of 75 to 115 mg on Mondays and Wednesdays (to approximate a dose of methadone of 60 to 100 mg daily); the Friday doses were 40 percent higher (to a maximal dose of 105 to 161 mg) to compensate for the longer interval before the next dose.32
Buprenorphine
Buprenorphine was administered at a dose of 16 to 32 mg on Mondays and Wednesdays (to approximate a dose of methadone of 60 to 100 mg daily)11; the Friday doses were 50 percent higher (24 to 48 mg).33
High-Dose and Low-Dose Methadone Groups
The doses for patients in the high-dose methadone group were in the upper range of doses generally used in clinical practice (60 to 100 mg). The dose in the low-dose control group (20 mg) was the minimally effective dose, according to the results of previous controlled trials.6,11
Procedures
The study had three phases: dose induction (weeks 1 and 2), maintenance (weeks 3 to 17), and disposition (weeks 18 to 28). On days of clinic attendance, all the patients received three solutions, only one of which contained active medication. Levomethadyl acetate and methadone were dispensed as oral solutions of different colors, and buprenorphine was dispensed sublingually as a 40 percent aqueous alcohol solution. Missed doses were treated according to preestablished blinded protocols developed by the investigators. Patients were discharged from the study if they were absent for five consecutive calendar days.
Dose Induction
Patients attended the clinic daily and received gradually increasing doses of medication. Patients assigned to levomethadyl acetate received 25 mg on day 1 and then began alternating between placebo and levomethadyl acetate, with 10-mg increases until the dose reached 75 mg. Buprenorphine was administered daily until day 7, starting at 4 mg on day 1 and increasing to 8 mg on days 2 through 7. On day 8, patients began alternating between placebo and 16-mg doses of buprenorphine. Patients assigned to high-dose methadone started with 20 mg, with 10-mg increases daily until the dose reached 60 mg. Patients assigned to low-dose methadone continued to receive 20 mg daily throughout the study.
Maintenance
Starting in week 3, patients attended the clinic three times a week, on Monday, Wednesday, and Friday. All patients received bottles of medication to take home for the other four days of the week.
Dose Increases
Patients receiving levomethadyl acetate, buprenorphine, or high-dose methadone could receive blinded increases in the dose starting in week 3 if they met preestablished criteria. Four dose increases were allowed, with one increase every two weeks. Doses were increased in 10-mg increments for levomethadyl acetate (on Monday and Wednesday, from 75 to 115 mg) and high-dose methadone (daily, from 60 to 100 mg), and in 4-mg increments for buprenorphine (on Monday and Wednesday, from 16 to 32 mg). Patients were evaluated weekly, and their doses were increased if they met two criteria: more than 83 percent attendance, with no Friday absences, and more than 33 percent of urine specimens opioid-positive during the previous week. The attendance criterion ensured that the patient received each intended dose before receiving further dose increases. The intent was to achieve individually optimized doses and to avoid confounding comparisons between drugs by potential differences in the adequacy of the dose.
Eighty percent of the patients in the levomethadyl acetate group, 96 percent of those in the buprenorphine group, and 91 percent of those in the high-dose methadone group met the criteria for dose increases. The mean maximal Monday and Wednesday doses were 100 mg of levomethadyl acetate, 27 mg of buprenorphine, 90 mg of high-dose methadone, and 20 mg of low-dose methadone. The average number of days required to achieve the maximal dose was 69 for levomethadyl acetate, 72 for buprenorphine, 68 for high-dose methadone, and 1 for low-dose methadone.
Rescue Treatment
A double-blind rescue procedure was implemented for patients with a poor response to treatment. Patients received rescue treatment if they attended more than 83 percent of clinic days, if they missed no Fridays, and if at least 66 percent of their urine specimens during the previous two weeks were opioid-positive. The patients also had either to request a dose increase or to report use of illicit opioids at more than 50 percent of the pretreatment level. The earliest they could receive rescue treatment was week 6 (for the low-dose methadone group) or week 13 (for all other groups). For rescue treatment, the patients were switched to an equivalent dose of methadone and followed clinically; they remained blinded to the treatment procedures, and data collection was continued, but data obtained after rescue treatment were excluded from analysis.
Take-Home Recall Procedure
To discourage methadone diversion and ensure compliance with medication, take-home bottles were randomly recalled. All take-home bottles scheduled for recall contained placebo. In a recall, patients were contacted by telephone and required to return their take-home bottles to the clinic; recalled bottles were replaced with a bottle containing placebo in the levomethadyl acetate and buprenorphine groups or with a bottle containing methadone (the scheduled dose) in the methadone groups.
Outcome Measures
The three primary outcome measures for assessing the efficacy of the medications were continued participation in the study (retention); opioid use, measured by the percentage of positive urine specimens, the degree of continuous abstinence from opioid use (defined by at least 12 consecutive opioid-free urine specimens), and the patients' own reports of frequency of use; and the patients' global ratings of the severity of their drug problem. Additional prespecified outcome measures were the percentage of cocaine-positive urine specimens, the duration of continuous abstinence from cocaine use, breath alcohol readings, side effects, and sex-related differences.
Statistical Analysis
Patient retention was calculated from the day of admission (first dose) to the day of study completion (119 days), the breaking of the dose code, the last administration of medication, or rescue. Kaplan–Meier estimates34 of mean retention times were compared among the groups by the Mantel–Cox log-rank test.35
Urine specimens were collected under observation on Monday, Wednesday, and Friday and analyzed on site for opioid and cocaine metabolites by the enzyme-multiplied immunoassay technique (Dade Behring Diagnostics, San Jose, Calif.). Findings of opioid or cocaine metabolites at a level of 300 ng or more per milliliter were considered positive results. Missed urine specimens were collected the following day (except Sundays). The percentage of missing samples was similar in all four groups (4.2 percent in the levomethadyl acetate group, 5.1 percent in the buprenorphine group, 3.0 percent in the high-dose methadone group, and 5.8 percent in the low-dose methadone group); these samples were considered positive for purposes of analysis. Breath alcohol levels (in grams per deciliter) were determined randomly on clinic days with a breath alcohol sensor (Alco-Sensor III, AlcoPro, Knoxville, Tenn.). The doses of medication were adjusted according to preestablished blinded protocols when the breath alcohol level was 0.05 g per deciliter or higher (26 doses were adjusted for this reason).
For each patient, we analyzed the weekly percentages of positive urine specimens separately for opioids and cocaine by multilevel analysis with an autoregression covariance structure36 for the week factor, using SAS Proc Mixed software (SAS Institute, Cary, N.C.). The restricted maximum-likelihood methods used in multilevel modeling have the flexibility to handle repeated-measures data sets with missing observations.37 We compensated for the potential effect of informative missing data by using study retention and the percentage of missed clinic visits as covariates.38 The percentages of patients who submitted at least 12 consecutive negative urine specimens were compared separately for opioids and cocaine by Fisher's exact test.39
The patients reported the frequency of opioid use each week, starting with the week before admission. Of 2993 scheduled reports, 196 were excluded from analysis because they were missing or were at least 3 SD from the mean: 6.8 percent of all scheduled reports for the levomethadyl acetate group, 7.4 percent for the buprenorphine group, 6.9 percent for the high-dose methadone group, and 8.5 percent for the low-dose methadone group. The data were analyzed according to the week with the multilevel analysis described above.
Every four weeks, the patients rated the severity of their drug problem from 0 (no drug problem) to 100 (worst ever). The data from the last assessment before completion of the study or discharge were analyzed by one-way analysis of variance.15 Fourteen patients dropped out before completing any severity assessment, and 14 of 206 patients missed their final assessment and were excluded from analysis (1.0 percent were missed in the levomethadyl acetate group, 1.5 percent in the buprenorphine group, 2.0 percent in the high-dose methadone group, and 2.4 percent in the low-dose methadone group).
All reported P values are two-tailed.
Results
Demographic Characteristics
There were no significant differences between groups in demographic characteristics or stratification variables (Table 1Table 1
Characteristics of the 220 Study Participants.).Study Retention
Patients were enrolled between January 17, 1996, and November 24, 1997. There were significant differences in study retention among the four groups. Pairwise comparisons showed significantly greater mean retention among patients receiving levomethadyl acetate (89±6 days), buprenorphine (96±4 days), or high-dose methadone (105±4 days) than among those receiving low-dose methadone (70±4 days, P< 0.001) (Figure 2AFigure 2
Results over the Course of the Trial.). The difference between patients taking high-dose methadone and those taking levomethadyl acetate was also significant (P=0.02), but not that between high-dose methadone and buprenorphine.Overall, 51 percent of the patients completed the 17-week trial (53 percent of the levomethadyl acetate group, 58 percent of the buprenorphine group, 73 percent of the high-dose methadone group, and 20 percent of the low-dose methadone group). When patients who received rescue treatment were included, the rates of retention were 60 percent, 64 percent, 84 percent, and 58 percent, respectively.
Opioid Use
Overall, patients receiving levomethadyl acetate, buprenorphine, and high-dose methadone submitted fewer opioid-positive urine specimens than did patients receiving low-dose methadone (Figure 2B and Table 2Table 2
Selected Outcome Measures.). The percentage of patients with at least 12 consecutive opioid-negative urine specimens differed significantly among groups (P=0.005), ranging from 36 percent in the levomethadyl acetate group to 8 percent in the low-dose methadone group (Table 2). There were no significant differences between groups in self-reported use of illicit opioids; however, each group did report a significant reduction in use over time (Figure 2C and Table 2). On a scale of 0 to 100, patients in the low-dose methadone group gave their drug problems the highest severity rating (mean, 53); the lowest rating was in the buprenorphine group (mean, 34) (Table 2).Alcohol and Cocaine Use and Side Effects of Treatment
Alcohol use was low at base line and throughout the study (only 3 percent of all breath samples had alcohol levels ≥0.01 g per deciliter). Only one participant regularly tested positive for alcohol; all others showed sporadic use, if any. Patients receiving low-dose methadone were the least likely to abstain from cocaine use (Table 2).
Side effects were assessed every four weeks by an open-ended questionnaire and coded to the Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART) system.40 The percentage of patients reporting side effects was similar among groups. At least one side effect was reported by 55 percent of the patients receiving levomethadyl acetate, 49 percent of those receiving buprenorphine, 45 percent of those receiving high-dose methadone, and 40 percent of those receiving low-dose methadone. The most common was constipation (21 percent of all reports), followed by nausea (8 percent) and dry mouth (6 percent). No toxic interactions associated with illicit-drug use were observed in any of the groups. There were no significant effects of sex on any outcome measure.
Discussion
Levomethadyl acetate, buprenorphine, and high-dose methadone were all effective in treating opioid dependence and were superior on multiple measures to low-dose methadone. The percentage of patients retained at 17 weeks compared favorably with rates reported elsewhere for these medications.11,14,23,24,27-29 The proportion of opiate-positive urine specimens and self-reported opioid use decreased over time.
As compared with patients taking low-dose methadone, those taking levomethadyl acetate had a significantly higher rate of continuous abstinence from opioids, and those taking high-dose methadone and buprenorphine had a trend toward a higher rate of continuous abstinence. The greater effectiveness of levomethadyl acetate during maintenance therapy may reflect more stable blood levels with less variation in trough-to-peak concentrations.41 Levomethadyl acetate, however, was less effective than high-dose methadone in terms of patient retention, particularly during the dose-induction period. The high dropout rate among patients taking levomethadyl acetate may be explained, in part, by the longer period required to achieve the targeted maintenance dose (nine days, as compared with five for methadone)42 and the greater reinforcement provided by daily treatment with a full agonist (methadone). Our difficulty in retaining patients during the induction of levomethadyl acetate treatment corroborates earlier findings.25,43-45
The low level of retention in the low-dose methadone group at 17 weeks (20 percent) reflects primarily the substantial proportion of patients receiving rescue treatment; the sharp decline in retention observed after week 6 in this group coincided with the earliest time that patients could receive rescue treatment. The fact that a large proportion of patients receiving low-dose methadone continued to use illicit opioids while they were receiving maintenance therapy at a dose of 20 mg of methadone is consistent with other reports that low doses of methadone are less effective in retaining patients in treatment programs and reducing illicit opioid use.6,11,14,28 Nevertheless, the rescue procedure was successful, since 81 percent of such patients in the low-dose methadone group completed 17 weeks of treatment.
Most of the development and evaluation research on buprenorphine has been based on daily doses. Our study used thrice-weekly doses and found that outcomes were approximately equivalent to those with either daily methadone or thrice-weekly levomethadyl acetate. Thus, thrice-weekly buprenorphine may also offer greater convenience to patients and clinic staff.
Urinalysis and self-reporting are surrogate measures of drug-taking behavior that differ in their sensitivity in detecting abstinence. Urinalysis may overestimate drug use; opioid use can decline by 75 percent (for example, from four times to once daily) and still yield 100 percent opioid-positive urine specimens, and frequent testing can allow carryover between consecutive tests. Self-reported drug use is open to either over- or underreporting. However, even though quantitative methods for more accurate detection of new drug use are currently being developed,45 both urinalysis and self-reports are accepted surrogate measures of drug use.46,47
The strengths of our study include the use of doses based on clinical criteria, ensuring that comparisons between drugs were based on individually optimized doses for three of the randomly assigned treatment groups. The use of a fixed-dose control group allowed us to demonstrate differences in outcome measures and to analyze a heterogeneous population of heroin users. The rescue procedure allowed us to retain 87 percent of all patients who received rescue treatment and allowed 66 percent of the total population to remain in treatment. Our rescue procedure also addressed potential ethical concerns.48
In summary, levomethadyl acetate, buprenorphine, and high-dose methadone were more effective than low-dose methadone in reducing the use of illicit opioids. As compared with low-dose methadone, levomethadyl acetate produced the longest duration of continuous abstinence; buprenorphine administered three times weekly was similar to levomethadyl acetate in terms of study retention and was similar to high-dose methadone in terms of abstinence.
Supported by grants (P50 DA05273, K02 DA00332, K05 DA00050, and Y01 DA40032) from the National Institute on Drug Abuse.
Dr. Johnson is or has been a consultant to Roxane Pharmaceuticals (manufacturer of levomethadyl acetate), Reckitt and Colman (manufacturer of buprenorphine), and Schering-Plough (distributor of buprenorphine).
We are indebted to Daniel A. Bloch, Ph.D. (for assistance with statistics); Mary Beth Mudric (assessments); Sherry Thomas (counseling); Connie Lowery and Mary Blackburn (nursing); Iona Johnson and Robert Mullen (pharmacy); Russell Lum, Lisa Marsch, and Jennifer Rosenbaum (research); Tim Mudric and Linda Felch (statistics); and John Yingling and Lisa Schade (technical support).
Source Information
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD 21224, where reprint requests should be addressed to Dr. Johnson.
- References
References
1
Office of National Drug Control Policy. National drug control strategy, 2000. Washington, D.C.: Government Printing Office, 2000.
2
Dole VP ,Nyswander M . A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965;193:646-650
Web of Science | Medline3
Jasinski DR ,Pevnick JS ,Griffith JD . Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35:501-516
CrossRef | Web of Science | Medline4
Lewis JW. Ring C-bridged derivatives of thebaine and oripavine. In: Braude MC, Harris LS, Smith JP, May EL, Villarreal JE, eds. Narcotic antagonists. Vol. 8 of Advances in biochemical psychopharmacology. New York: Raven Press, 1974:123-36.
5
Newman RG ,Whitehill WB . Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979;2:485-488
CrossRef | Web of Science | Medline6
Strain EC ,Stitzer ML ,Liebson IA ,Bigelow GE . Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993;119:23-27
Web of Science | Medline7
Strain EC ,Bigelow GE ,Liebson IA ,Stitzer ML . Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999;281:1000-1005
CrossRef | Web of Science | Medline8
Caplehorn JR ,Bell J . Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991;154:195-199[Erratum, Med J Aust 1993;159:640.]
Web of Science | Medline9
Gerstein DR, Harwood HJ, eds. Treating drug problems. Vol. 1. A study of the evolution, effectiveness and financing of public and private drug treatment systems. Washington, D.C.: National Academy Press, 1990.
10
Gunne LM, Grönbladh L. The Swedish methadone maintenance program. In: Serban G, ed. Social and medical aspects of drug abuse. Jamaica, N.Y.: Spectrum, 1984:205-13.
11
Johnson RE ,Jaffe JH ,Fudala PJ . A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267:2750-2755
CrossRef | Web of Science | Medline12
Eissenberg T ,Bigelow GE ,Strain EC , et al. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: a randomized clinical trial. JAMA 1997;277:1945-1951
CrossRef | Web of Science | Medline13
Oliveto AH ,Farren C ,Kosten TR . Effect of LAAM dose on opiate use in opioid-dependent patients: a pilot study. Am J Addict 1998;7:272-282
Web of Science | Medline14
Schottenfeld RS ,Pakes JR ,Oliveto A ,Zeidonis D ,Kosten TR . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997;54:713-720
Web of Science | Medline15
Ling W ,Charuvastra C ,Collins JF , et al. Buprenorphine maintenance treatment of opioid dependence: a multicenter, randomized clinical trial. Addiction 1998;93:475-486
CrossRef | Web of Science | Medline16
Walsh SL ,Preston KL ,Bigelow GE ,Stitzer ML . Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995;274:361-372
Web of Science | Medline17
Walsh SL ,June HL ,Schuh KJ ,Preston KL ,Bigelow GE ,Stitzer ML . Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995;119:268-276
CrossRef | Web of Science | Medline18
Amass L ,Bickel WK ,Higgins ST ,Hughes JR . A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 1994;13:33-45
CrossRef | Web of Science | Medline19
Bickel WK ,Amass L ,Crean JP ,Badger GJ . Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl) 1999;146:111-118
CrossRef | Web of Science | Medline20
Fudala PJ ,Jaffe JH ,Dax EM ,Johnson RE . Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990;47:525-534
CrossRef | Web of Science | Medline21
Johnson RE ,Eissenberg T ,Stitzer ML ,Strain EC ,Liebson IA ,Bigelow GE . Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 1995;40:27-35
CrossRef | Web of Science | Medline22
Jaffe JH ,Senay EC . Methadone and l-methadyl acetate: use in management of narcotics addicts. JAMA 1971;216:1303-1305
CrossRef | Web of Science | Medline23
Jaffe JH ,Senay EC ,Schuster CR ,Renault PR ,Smith B ,DiMenza S . Methadyl acetate vs methadone: a double-blind study in heroin users. JAMA 1972;222:437-442
CrossRef | Web of Science | Medline24
Ling W ,Charuvastra C ,Kaim SC ,Klett CJ . Methadyl acetate and methadone as maintenance treatments for heroin addicts: a Veterans Administration cooperative study. Arch Gen Psychiatry 1976;33:709-720
Web of Science | Medline25
Savage C ,Karp EG ,Curran SF ,Hanlon TE ,McCabe OL . Methadone/LAAM maintenance: a comparison study. Compr Psychiatry 1976;17:415-424
CrossRef | Web of Science | Medline26
Karp-Gelernter E ,Savage C ,McCabe OL . Evaluation of clinic attendance schedules for LAAM and methadone: a controlled study. Int J Addict 1982;17:805-813
Medline27
Kosten TR ,Schottenfeld R ,Ziedonis D ,Falcioni J . Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993;181:358-364
CrossRef | Web of Science | Medline28
Ling W ,Wesson DR ,Charuvastra C ,Klett CJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996;53:401-407
CrossRef | Web of Science | Medline29
Strain EC ,Stitzer ML ,Liebson IA ,Bigelow GE . Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) 1994;116:401-406
CrossRef | Web of Science | Medline30
Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
31
Piantadosi S. Clinical trials: a methodologic perspective. New York: John Wiley, 1997.
32
Physicians' desk reference. 54th ed. Montvale, N.J.: Medical Economics, 2000.
33
Perez de los Cobos J,
Martin S ,Etcheberrigaray A , et al. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend 2000;59:223-233
CrossRef | Web of Science | Medline34
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science35
Peto R ,Peto J . Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972;135:185-207
CrossRef | Web of Science36
Singer JD . Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 1998;24:323-35537
Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data. Oxford, England: Clarendon Press, 1995.
38
Follman D ,Wu M . An approximate generalized linear model with random effects for informative missing data. Biometrics 1995;51:151-168
CrossRef | Web of Science | Medline39
Siegel S. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956:107.
40
Food and Drug Administration. COSTART. 2nd ed. Rockville, Md.: Department of Health and Human Services, 1985.
41
Henderson GL ,Weinberg JA ,Hargreaves WA ,Lau DHM ,Tyler J ,Baker B . Accumulation of l-α-acetylmethadol (LAAM) and active metabolites in plasma following chronic administration. J Anal Toxicol 1977;1:1-5
Web of Science42
Henderson GL ,Wilson BK ,Lau DHM . Plasma l-alpha-acetylmethadol (LAAM) after acute and chronic administration. Clin Pharmacol Ther 1977;21:16-25
Web of Science | Medline43
Ling W ,Klett CJ ,Gillis RD . A cooperative clinical study of methadyl acetate. I. Three-times-a-week regimen. Arch Gen Psychiatry 1978;35:345-353
Web of Science | Medline44
Senay EC ,Dorus W ,Renault PF . Methadyl acetate and methadone: an open comparison. JAMA 1977;237:138-142
CrossRef | Web of Science | Medline45
Jones HE ,Strain EC ,Bigelow GE , et al. Induction with levomethadyl acetate: safety and efficacy. Arch Gen Psychiatry 1998;55:729-736
CrossRef | Web of Science | Medline46
Preston KL, Silverman K, Schuster CR, Cone EJ. Comparison of self-reported drug use with quantitative and qualitative urinalysis for assessment of drug use in treatment studies. In: Harrison L, Hughes A, eds. The validity of self-reported drug use: improving the accuracy of survey estimates. NIDA research monograph 167. Rockville, Md.: National Institute on Drug Abuse, 1997:130-45. (NIH publication no. 97-4147.)
47
Darke S . Self-report among injecting drug users: a review. Drug Alcohol Depend 1998;51:253-263
CrossRef | Web of Science | Medline48
Imber SD, Glanz LM, Elkin I, Sotsky SM, Boyer JL, Leber WR. Ethical issues in psychotherapy research: problems in a collaborative clinical trials study. In: Kazdin AE, ed. Methodological issues and strategies in clinical research. Washington, D.C.: American Psychological Association, 1992:665-86.
- Citing Articles (207)
Citing Articles
1
Peter D. Friedmann, Randall Hoskinson, Michael Gordon, Robert Schwartz, Timothy Kinlock, Kevin Knight, Patrick M. Flynn, Wayne N. Welsh, Lynda A. R. Stein, Stanley Sacks, Daniel J. O’Connell, Hannah K. Knudsen, Michael S. Shafer, Elizabeth Hall, Linda K. Frisman, for the MAT Working Group of CJ-DAT. (2012) Medication-Assisted Treatment in Criminal Justice Agencies Affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, Barriers, and Intentions. Substance Abuse 33:1, 9-18
CrossRef2
Gavin Bart, Qi Wang, James S. Hodges, Chris Nolan, Gregory Carlson. (2012) Superior methadone treatment outcome in Hmong compared with non-Hmong patients. Journal of Substance Abuse Treatment
CrossRef3
Lindsey Richardson, Evan Wood, Julio Montaner, Thomas Kerr. (2012) Addiction treatment-related employment barriers: The impact of methadone maintenance. Journal of Substance Abuse Treatment
CrossRef4
Nancy D. Campbell, Anne M. Lovell. (2012) The history of the development of buprenorphine as an addiction therapeutic. Annals of the New York Academy of Sciencesno-no
CrossRef5
Ayman Fareed, Sreedevi Vayalapalli, Jennifer Casarella, Karen Drexler. (2011) Treatment Outcome for Flexible Dosing Buprenorphine Maintenance Treatment. The American Journal of Drug and Alcohol Abuse1-6
CrossRef6
Traci R. Rieckmann, Anne E. Kovas, Bentson H. McFarland, Amanda J. Abraham. (2011) A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. Journal of Substance Abuse Treatment 41:4, 374-385
CrossRef7
David E. Moody, Wenfang B. Fang, Jerdravee Morrison, Elinore McCance-Katz. (2011) Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug and Alcohol Dependence 118:2-3, 479-483
CrossRef8
Yan He, Fei-Xiang Wu, Xue-Rong Miao, Xue-Wu Xu, Yu-Ming Sun, Cai -Yang Chen, Wei-Feng Yu. (2011) Suppression of acute morphine withdrawal syndrome by adenovirus-mediated β-endorphin in rats. Brain Research 1422, 13-19
CrossRef9
Leslie Amass, Vilma Pukeleviciene, Emilis Subata, António Rocha Almeida, Maria Chiara Pieri, Pietro D'Egidio, Zdenka Stankova, António Costa, Bobby P. Smyth, Slavko Sakoman, Yan Wei, John Strang. (2011) A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Addictionno-no
CrossRef10
Prabhat Chand, Pratima Murthy. (2011) Short-term outcome of take-home prescriptions for opioid dependence: a clinic-based study. Journal of Substance Use1-11
CrossRef11
Michelle R. Lofwall, Martha J. Wunsch, Paul A. Nuzzo, Sharon L. Walsh. (2011) Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. Journal of Substance Abuse Treatment 41:3, 321-329
CrossRef12
Raminta Daniulaityte, Russel Falck, Robert G. Carlson. (2011) Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug and Alcohol Dependence
CrossRef13
Erik W. Gunderson, Frances R. Levin, Margaret M. Rombone, Suzanne K. Vosburg, Herbert D. Kleber. (2011) Improving Temporal Efficiency of Outpatient Buprenorphine Induction. The American Journal on Addictions 20:5, 397-404
CrossRef14
Margaret Haney, Eric Rubin, Richard W. Foltin. (2011) Aripiprazole maintenance increases smoked cocaine self-administration in humans. Psychopharmacology 216:3, 379-387
CrossRef15
Chunqing Lin, Roger Detels. (2011) A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China. Drug and Alcohol Dependence 117:1, 45-49
CrossRef16
Sarah A. Savage, Amanda J. Abraham, Hannah K. Knudsen, Tanja C. Rothrauff, Paul M. Roman. (2011) Timing of buprenorphine adoption by privately funded substance abuse treatment programs: The role of institutional and resource-based interorganizational linkages. Journal of Substance Abuse Treatment
CrossRef17
Chinazo O. Cunningham, Angela Giovanniello, Xuan Li, Hillary V. Kunins, Robert J. Roose, Nancy L. Sohler. (2011) A comparison of buprenorphine induction strategies: Patient-centered home-based inductions versus standard-of-care office-based inductions. Journal of Substance Abuse Treatment 40:4, 349-356
CrossRef18
Jeremie Jegu, Adeline Gallini, Pauline Soler, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (2011) Slow-release oral morphine for opioid maintenance treatment: a systematic review. British Journal of Clinical Pharmacology 71:6, 832-843
CrossRef19
David Hersh, Sherri L. Little, Alice Gleghorn. (2011) Integrating Buprenorphine Treatment into a Public Healthcare System: The San Francisco Department of Public Health's Office-Based Buprenorphine Pilot Program. Journal of Psychoactive Drugs 43:2, 136-145
CrossRef20
Inmaculada Jiménez-Nácher, Elena Alvarez, Judit Morello, Sonia Rodriguez-Nóvoa, Susana de Andrés, Vincent Soriano. (2011) Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opinion on Drug Metabolism & Toxicology 7:4, 457-477
CrossRef21
I.-Chun Chen, Wei-Chu Chie, Hai-Go Hwu, Sun-Yuan Chou, Yun-Chiang Yeh, Chun-Yen Yu, Happy Kuy-Lok Tan. (2011) Alcohol use problem among patients in methadone maintenance treatment in Taiwan. Journal of Substance Abuse Treatment 40:2, 142-149
CrossRef22
Frederick L Altice, R Douglas Bruce, Gregory M Lucas, Paula J Lum, P Todd Korthuis, Timothy P Flanigan, Chinazo O Cunningham, Lynn E Sullivan, Pamela Vergara-Rodriguez, David A Fiellin, Adan Cajina, Michael Botsko, Vijay Nandi, Marc N Gourevitch, Ruth Finkelstein. (2011) HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 56, S22-S32
CrossRef23
David A Fiellin, Linda Weiss, Michael Botsko, James E Egan, Frederick L Altice, Lauri B Bazerman, Amina Chaudhry, Chinazo O Cunningham, Marc N Gourevitch, Paula J Lum, Lynn E Sullivan, Richard S Schottenfeld, Patrick G OʼConnor. (2011) Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone. JAIDS Journal of Acquired Immune Deficiency Syndromes 56, S33-S38
CrossRef24
Linda Weiss, Julie Netherland, James E Egan, Timothy P Flanigan, David A Fiellin, Ruth Finkelstein, Frederick L Altice. (2011) Integration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative. JAIDS Journal of Acquired Immune Deficiency Syndromes 56, S68-S75
CrossRef25
Linda Weiss, James E Egan, Michael Botsko, Julie Netherland, David A Fiellin, Ruth Finkelstein. (2011) The BHIVES Collaborative: Organization and Evaluation of a Multisite Demonstration of Integrated Buprenorphine/Naloxone and HIV Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes 56, S7-S13
CrossRef26
Jermaine D Jones, Maria A Sullivan, Jeanne Manubay, Suzanne K Vosburg, Sandra D Comer. (2011) The Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Patients with Chronic, Non-Malignant Pain who are Maintained on Sublingual Buprenorphine/Naloxone. Neuropsychopharmacology 36:2, 411-422
CrossRef27
Ayman Fareed, Sreedevi Vayalapalli, Steven Stout, Jennifer Casarella, Karen Drexler, Stephen P. Bailey. (2010) Effect of Methadone Maintenance Treatment on Heroin Craving, a Literature Review. Journal of Addictive Diseases 30:1, 27-38
CrossRef28
Jones, Hendrée E., Kaltenbach, Karol, Heil, Sarah H., Stine, Susan M., Coyle, Mara G., Arria, Amelia M., O'Grady, Kevin E., Selby, Peter, Martin, Peter R., Fischer, Gabriele, . (2010) Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure. New England Journal of Medicine 363:24, 2320-2331
Full Text29
Hayley Pinto, Vivienne Maskrey, Louise Swift, Daphne Rumball, Ajay Wagle, Richard Holland. (2010) The SUMMIT Trial:. Journal of Substance Abuse Treatment 39:4, 340-352
CrossRef30
Icro Maremmani, Gilberto Gerra. (2010) Buprenorphine-Based Regimens and Methadone for the Medical Management of Opioid Dependence: Selecting the Appropriate Drug for Treatment. The American Journal on Addictions 19:6, 557-568
CrossRef31
Ayman Fareed, Sreedevi Vayalapalli, Jennifer Casarella, Richard Amar, Karen Drexler. (2010) Heroin anticraving medications: A systematic review. The American Journal of Drug and Alcohol Abuse 36:6, 332-341
CrossRef32
Michael D. Stein, Debra S. Herman, Malyna Kettavong, Patricia A. Cioe, Peter D. Friedmann, Tahir Tellioglu, Bradley J. Anderson. (2010) Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. Journal of Substance Abuse Treatment 39:2, 157-166
CrossRef33
Ezechukwu Awgu, Stephen Magura, Andrew Rosenblum. (2010) Heroin-Dependent Inmates' Experiences with Buprenorphine or Methadone Maintenance. Journal of Psychoactive Drugs 42:3, 339-346
CrossRef34
Angela N. Duke, Christopher J. Correia, Sharon L. Walsh, George E. Bigelow, Eric C. Strain. (2010) Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. Psychopharmacology 211:3, 303-312
CrossRef35
Donald R. Wesson, David E. Smith. (2010) Buprenorphine in the Treatment of Opiate Dependence. Journal of Psychoactive Drugs 42:2, 161-175
CrossRef36
Edwin A. Salsitz, Christopher C. Holden, Susan Tross, Ann Nugent. (2010) Transitioning Stable Methadone Maintenance Patients to Buprenorphine Maintenance. Journal of Addiction Medicine 4:2, 88-92
CrossRef37
Gianluca Quaglio, Cristian Pattaro, Gilberto Gerra, Paolo Mezzelani, Linda Montanari, Don C. Des Jarlais, Fabio Lugoboni. (2010) Buprenorphine in Maintenance Treatment: Experience among Italian Physicians in Drug Addiction Centers. American Journal on Addictions 19:3, 222-230
CrossRef38
Enrico Moratti, Hamid Kashanpour, Tiziana Lombardelli, Maria Maisto. (2010) Intravenous Misuse of Buprenorphine. Clinical Drug Investigation 30, 3-11
CrossRef39
Sandra D. Comer, Maria A. Sullivan, Suzanne K. Vosburg, Jeanne Manubay, Leslie Amass, Ziva D. Cooper, Phillip Saccone, Herbert D. Kleber. (2010) Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 105:4, 709-718
CrossRef40
Debra F. Hobbins. (2010) Case Report: Methadone Maintenance Dose of 1200 mg/day in an Ultra-rapid Metabolizer. Journal of Addictions Nursing 21:1, 22-36
CrossRef41
Timothy W. Kinlock, Michael S. Gordon, Robert P. Schwartz, Terrence T. Fitzgerald. (2010) Developing and Implementing a New Prison-Based Buprenorphine Treatment Program. Journal of Offender Rehabilitation 49:2, 91-109
CrossRef42
Ayman Fareed, Jennifer Casarella, Richard Amar, Sreedevi Vayalapalli, Karen Drexler. (2010) Methadone Maintenance Dosing Guideline for Opioid Dependence, a Literature Review. Journal of Addictive Diseases 29:1, 1-14
CrossRef43
Ayman Fareed, Sreedevi Vayalapalli, Johnita Byrd-Sellers, Jennifer Casarella, Karen Drexler, Richard Amar, Jocelyn Smith-Cox, Tamara Shaw Lutchman. (2010) Onsite QTc Interval Screening for Patients in Methadone Maintenance Treatment. Journal of Addictive Diseases 29:1, 15-22
CrossRef44
T.V. Parran, C.A. Adelman, B. Merkin, M.E. Pagano, R. Defranco, R.A. Ionescu, A.G. Mace. (2010) Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug and Alcohol Dependence 106:1, 56-60
CrossRef45
Robert P. Schwartz, Jerome H. Jaffe, Kevin E. O'Grady, Babita Das, David A. Highfield, Monique E. Wilson. (2009) Scaling-up interim methadone maintenance: Treatment for 1,000 heroin-addicted individuals. Journal of Substance Abuse Treatment 37:4, 362-367
CrossRef46
Nidal Moukaddam, David V. Herin, Angela Stotts, Anne Hamilton Dougherty, Charles Green, Marc Mooney, Ann Garcia, Richard A. Meisch, Katherine Cowan, Frederick Gerard Moeller, Joy M. Schmitz, John Grabowski. (2009) Comparison of 3 L-α-acetyl-methadol (LAAM) Maintenance Strategies for Heroin Dependence. Addictive Disorders & Their Treatment 8:4, 191-200
CrossRef47
Ayman Fareed, Jennifer Casarella, Mary Roberts, Mary Sleboda, Richard Amar, Shreedevi Vayalapalli, Karen Drexler. (2009) High Dose versus Moderate Dose Methadone Maintenance: Is There a Better Outcome?. Journal of Addictive Diseases 28:4, 399-405
CrossRef48
Katherine J. Deans, Peter C. Minneci, Robert L. Danner, Peter Q. Eichacker, Charles Natanson. (2009) Practice Misalignments in Randomized Controlled Trials: Identification, Impact, and Potential Solutions. Anesthesia & Analgesia1
CrossRef49
Timothy W. Kinlock, Michael S. Gordon, Robert P. Schwartz, Terrence T. Fitzgerald, Kevin E. O'Grady. (2009) A randomized clinical trial of methadone maintenance for prisoners: Results at 12 months postrelease. Journal of Substance Abuse Treatment 37:3, 277-285
CrossRef50
(2009) Does alcohol play a role in QT prolongation?. Internal Medicine Journal 39:9, 631-632
CrossRef51
Oviedo-Joekes, Eugenia, Brissette, Suzanne, Marsh, David C., Lauzon, Pierre, Guh, Daphne, Anis, Aslam, Schechter, Martin T., . (2009) Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction. New England Journal of Medicine 361:8, 777-786
Full Text52
Jason White, James Bell, John B. Saunders, Paul Williamson, Maria Makowska, Aaron Farquharson, Katherine L. Beebe. (2009) Open-label dose-finding trial of buprenorphine implants (Probuphine)® for treatment of heroin dependence. Drug and Alcohol Dependence 103:1-2, 37-43
CrossRef53
Gayle Ridge, Michael Gossop, Nicholas Lintzeris, John Witton, John Strang. (2009) Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment 37:1, 95-100
CrossRef54
Ayman Fareed, Jennifer Casarella, Richard Amar, Karen Drexler. (2009) Dose-Dependent Cognitive Impairment in an Elder Methadone-Maintained Patient. Journal of Addiction Medicine 3:2, 109-110
CrossRef55
Maja Meise, Xi Wang, Marie-Luise Sauter, Yan-ping Bao, Jie Shi, Zhi-min Liu, Lin Lu. (2009) Harm reduction for injecting opiate users: an update and implications in China. Acta Pharmacologica Sinica 30:5, 513-521
CrossRef56
Jagadisha Thirthalli, Prabhat K Chand. (2009) The implications of medication development in the treatment of substance use disorders in developing countries. Current Opinion in Psychiatry 22:3, 274-280
CrossRef57
Scott E. Hadland, Thomas Kerr, Kathy Li, Julio S. Montaner, Evan Wood. (2009) Access to drug and alcohol treatment among a cohort of street-involved youth. Drug and Alcohol Dependence 101:1-2, 1-7
CrossRef58
Joshua D. Lee, Ellie Grossman, Danae DiRocco, Marc N. Gourevitch. (2009) Home Buprenorphine/Naloxone Induction in Primary Care. Journal of General Internal Medicine 24:2, 226-232
CrossRef59
Jennifer S. Orman, Gillian M. Keating. (2009) Buprenorphine/Naloxone. Drugs 69:5, 577-607
CrossRef60
Stephen Magura, Joshua D. Lee, Jason Hershberger, Herman Joseph, Lisa Marsch, Carol Shropshire, Andrew Rosenblum. (2009) Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug and Alcohol Dependence 99:1-3, 222-230
CrossRef61
Ricardo A. Cruciani. (2008) Methadone: To ECG or Not to ECG…That Is Still the Question. Journal of Pain and Symptom Management 36:5, 545-552
CrossRef62
Alexander Y. Walley, Julie K. Alperen, Debbie M. Cheng, Michael Botticelli, Carolyn Castro-Donlan, Jeffrey H. Samet, Daniel P. Alford. (2008) Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers. Journal of General Internal Medicine 23:9, 1393-1398
CrossRef63
Michael Soyka, Christina Zingg, Gabriele Koller, Heinrich Kuefner. (2008) Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. The International Journal of Neuropsychopharmacology 11:05,
CrossRef64
Michael S. Gordon, Timothy W. Kinlock, Robert P. Schwartz, Kevin E. O’Grady. (2008) A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction 103:8, 1333-1342
CrossRef65
Margaret Haney, Roger Spealman. (2008) Controversies in translational research: drug self-administration. Psychopharmacology 199:3, 403-419
CrossRef66
Johan Kakko, Markus Heilig, Ihsan Sarman. (2008) Buprenorphine and methadone treatment of opiate dependence during pregnancy: Comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug and Alcohol Dependence 96:1-2, 69-78
CrossRef67
Peter Athanasos, Aaron L. Farquharson, Peggy Compton, Peter Psaltis, Justin Hay. (2008) Electrocardiogram Characteristics of Methadone and Buprenorphine Maintained Subjects. Journal of Addictive Diseases 27:3, 31-35
CrossRef68
Richard Saitz, Mary Jo Larson, Colleen LaBelle, Jessica Richardson, Jeffrey H. Samet. (2008) The Case for Chronic Disease Management for Addiction. Journal of Addiction Medicine 2:2, 55-65
CrossRef69
Richard P Mattick, Jo Kimber, Courtney Breen, Marina Davoli, Richard P Mattick. 2008. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. .
CrossRef70
Gianluca Quaglio, Fabio Lugoboni, Cristian Pattaro, Barbara Melara, Paolo Mezzelani, Don C. Des Jarlais. (2008) Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment. Drug and Alcohol Dependence 94:1-3, 12-18
CrossRef71
R. Douglas Bruce, Frederick L. Altice, Gerald Friedland. 2008. HIV Disease Among Substance Users: Treatment Issues. , 513-526.
CrossRef72
Erik W Gunderson, David A Fiellin. (2008) Office-Based Maintenance Treatment of Opioid Dependence. CNS Drugs 22:2, 99-111
CrossRef73
Timothy W. Kinlock, Michael S. Gordon, Robert P. Schwartz, Kevin O’Grady, Terrence T. Fitzgerald, Monique Wilson. (2007) A randomized clinical trial of methadone maintenance for prisoners: Results at 1-month post-release. Drug and Alcohol Dependence 91:2-3, 220-227
CrossRef74
James Bell, Marian Shanahan, Carolyn Mutch, Felicity Rea, Anni Ryan, Robert Batey, Adrian Dunlop, Adam Winstock. (2007) A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 102:12, 1899-1907
CrossRef75
Sharon Reif, Cindy Parks Thomas, Stanley S. Wallack. (2007) Factors Determining How Early Adopter Physicians Use Buprenorphine in Treatment. Journal of Addiction Medicine 1:4, 205-212
CrossRef76
Paolo Mannelli, Ashwin A. Patkar, Kathleen Peindl, Heather W. Murray, Li-Tzy Wu, Robert Hubbard. (2007) Effectiveness of Low-Dose Naltrexone in the Post-Detoxification Treatment of Opioid Dependence. Journal of Clinical Psychopharmacology 27:5, 468-474
CrossRef77
Andrew Black, Sanaur Khan, Roxanne Brown, Peter Sharp, Harold Chatfield, Clare McGuiness. (2007) An evaluation of opioid replacement pharmacotherapy in an urban Aboriginal Health Service. Australian and New Zealand Journal of Public Health 31:5, 428-432
CrossRef78
M. Douglas Anglin, Bradley T. Conner, Jeffery Annon, Douglas Longshore. (2007) Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status. Addiction 102:9, 1432-1442
CrossRef79
Icro Maremmani, Pier Paolo Pani, Matteo Pacini, Giulio Perugi. (2007) Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. Journal of Substance Abuse Treatment 33:1, 91-98
CrossRef80
Susan D. Whitley, Hillary V. Kunins, Julia H. Arnsten, Marc N. Gourevitch. (2007) Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services. Journal of Substance Abuse Treatment 33:1, 85-90
CrossRef81
Georg B Ehret, Jules A Desmeules, Barbara Broers. (2007) Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opinion on Drug Safety 6:3, 289-303
CrossRef82
Robin DiFrancesco, Margaret A. Fischl, Julie Donnelly, Barry S. Zingman, Elinore F. McCance-Katz, David E. Moody, Richard C. Reichman, Barbara Gripshover, Gene D. Morse. (2007) Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Journal of Pharmaceutical and Biomedical Analysis 44:1, 188-195
CrossRef83
(2007) Illicit opioid use in the 21st century: witnessing a paradigm shift?. Addiction 102:4, 499-501
CrossRef84
Frank J. Vocci. 2007. Opiates and Addiction. .
CrossRef85
R. Douglas Bruce, Frederick L. Altice. (2007) Clinical Care of the HIV-Infected Drug User. Infectious Disease Clinics of North America 21:1, 149-179
CrossRef86
Hannah K. Knudsen, Lori J. Ducharme, Paul M. Roman. (2007) The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence 87:2-3, 164-174
CrossRef87
Daniel P. Alford, Colleen T. LaBelle, Jessica M. Richardson, James J. O’Connell, Carole A. Hohl, Debbie M. Cheng, Jeffrey H. Samet. (2007) Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting. Journal of General Internal Medicine 22:2, 171-176
CrossRef88
Jason M White, Olga V Lopatko. (2007) Opioid maintenance: a comparative review of pharmacological strategies. Expert Opinion on Pharmacotherapy 8:1, 1-11
CrossRef89
John C.M. Brust. 2007. Les opioïdes. , 53-127.
CrossRef90
M. P. Carrieri, L. Amass, G. M. Lucas, D. Vlahov, A. Wodak, G. E. Woody. (2006) Buprenorphine Use: The International Experience. Clinical Infectious Diseases 43:Supplement 4, S197-S215
CrossRef91
D. A. Fiellin, G. H. Friedland, M. N. Gourevitch. (2006) Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 43:Supplement 4, S173-S177
CrossRef92
F. L. Altice, L. E. Sullivan, D. Smith-Rohrberg, S. Basu, S. Stancliff, L. Eldred. (2006) The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 43:Supplement 4, S178-S183
CrossRef93
Paula J. Lum, Jacqueline Peterson Tulsky. (2006) The medical management of opioid dependence in HIV primary care settings. Current HIV/AIDS Reports 3:4, 195-204
CrossRef94
Christian Haasen, Wim van den Brink. (2006) Innovations in agonist maintenance treatment of opioid-dependent patients. Current Opinion in Psychiatry 19:6, 631-636
CrossRef95
David H. Epstein, Kenzie L. Preston, Jane Stewart, Yavin Shaham. (2006) Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology 189:1, 1-16
CrossRef96
David C. Lott, Eric C. Strain, Robert K. Brooner, George E. Bigelow, Rolley E. Johnson. (2006) HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate hydrochloride, buprenorphine, and methadone. Journal of Substance Abuse Treatment 31:2, 187-194
CrossRef97
Elizabeth Cho, Helen Dermatis, Marc Galanter. (2006) Buprenorphine for Heroin Addicts. Substance Abuse 27:1-2, 1-3
CrossRef98
Benjamin Maas, Thomas Kerr, Nadia Fairbairn, Julio Montaner, Evan Wood. (2006) Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence. Expert Opinion on Drug Metabolism & Toxicology 2:4, 533-543
CrossRef99
Mary E Fournier, Sharon Levy. (2006) Recent trends in adolescent substance use, primary care screening, and updates in treatment options. Current Opinion in Pediatrics 18:4, 352-358
CrossRef100
Fiellin, David A., Pantalon, Michael V., Chawarski, Marek C., Moore, Brent A., Sullivan, Lynn E., O'Connor, Patrick G., Schottenfeld, Richard S., . (2006) Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence. New England Journal of Medicine 355:4, 365-374
Full Text101
Steven W. Villafranca, John D. McKellar, Jodie A. Trafton, Keith Humphreys. (2006) Predictors of retention in methadone programs: A signal detection analysis. Drug and Alcohol Dependence 83:3, 218-224
CrossRef102
Stephane Pirnay, Françoise Hervé, Stéphane Bouchonnet, Bérengère Perrin, Frédéric J. Baud, Ivan Ricordel. (2006) Liquid chromatographic–electrospray ionization mass spectrometric quantitative analysis of buprenorphine, norbuprenorphine, nordiazepam and oxazepam in rat plasma. Journal of Pharmaceutical and Biomedical Analysis 41:4, 1135-1145
CrossRef103
Hannah K. Knudsen, Lori J. Ducharme, Paul M. Roman. (2006) Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment 30:4, 363-373
CrossRef104
Wei Huang, David E. Moody, Elinore F. McCance-Katz. (2006) The In Vivo Glucuronidation of Buprenorphine and Norbuprenorphine Determined by Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry. Therapeutic Drug Monitoring 28:2, 245-251
CrossRef105
Sofie R. Kleppner, Raj Patel, Lauren C. Costantini, Joseph McDonough. (2006) In-vitro and in-vivo characterization of a buprenorphine delivery system. Journal of Pharmacy and Pharmacology 58:3, 295-302
CrossRef106
Steffanie A. Strathdee, Thomas L. Patterson. (2006) Behavioral Interventions for HIV-Positive and HCV-Positive Drug users. AIDS and Behavior 10:2, 115-130
CrossRef107
Martin Schmidt, Michael v. Cranach, Stefan Egger. (2006) Anforderungen an ein regionalisiertes medizinisches Versorgungssystem für Drogenabhängige. Wiener Medizinische Wochenschrift 156:3-4, 102-110
CrossRef108
Iraj Shahramian ., Muhmoodzadeh Sagheb Z. Heidari .. (2006) Volumetry of Brain of Rat Following Methadone and Buprenorphine Administration. International Journal of Pharmacology 2:2, 253-255
CrossRef109
Iraj Shahramian ., Abdolvahab Moradi ., Malek Rakhshani ., Abbas-Ali Moein ., Mahin Badakhsh .. (2006) A Comparison of Buprenorphine and Methadone Treatment of Heroine Dependency. Trends in Medical Research 1:1, 27-30
CrossRef110
Marek C. Chawarski, David E. Moody, Juliana Pakes, Patrick G. O'Connor, Richard S. Schottenfeld. (2005) Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms. Journal of Substance Abuse Treatment 29:4, 307-312
CrossRef111
(2005) New horizons: sustained release morphine as agonist treatment. Addiction 100:12, 1758-1759
CrossRef112
Iraj Shahramian ., Abdolvahab Moradi ., Lila Roosta ., Malek Rakhshani ., Abbas-Ali Moein ., Saeed Shakeri ., Azad-Reza Mansorian .. (2005) A Comparison of Buprenorphine and Methadone Treatment of Heroine Dependency. Pakistan Journal of Biological Sciences 8:12, 1690-1692
CrossRef113
Michael D. Stein, Patricia Cioe, Peter D. Friedmann. (2005) Buprenorphine Retention in Primary Care. Journal of General Internal Medicine 20:11, 1038-1041
CrossRef114
Julia Hanna, David J.R. Foster, Amy Salter, Andrew A. Somogyi, Jason M. White, Felix Bochner. (2005) Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. British Journal of Clinical Pharmacology 60:4, 404-413
CrossRef115
Sandra D. Comer, Ellen A. Walker, Eric D. Collins. (2005) Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 181:4, 664-675
CrossRef116
Qing Ma, Olanrewaju O Okusanya, Patrick F Smith, Robert DiCenzo, Judianne C Slish, Linda M Catanzaro, Alan Forrest, Gene D Morse. (2005) Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opinion on Drug Metabolism & Toxicology 1:3, 473-485
CrossRef117
Christopher M Doran. (2005) Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research 5:5, 583-591
CrossRef118
Andrew J. Saxon, Dennis McCarty. (2005) Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacology & Therapeutics 108:1, 119-128
CrossRef119
L. E. Sullivan, D. A. Fiellin. (2005) Buprenorphine: Its Role in Preventing HIV Transmission and Improving the Care of HIV-Infected Patients with Opioid Dependence. Clinical Infectious Diseases 41:6, 891-896
CrossRef120
Hannah K. Knudsen, Lori J. Ducharme, Paul M. Roman, Tanja Link. (2005) Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment 29:2, 95-106
CrossRef121
Harald Eder, Reinhold Jagsch, Dominik Kraigher, Andjela Primorac, Nina Ebner, Gabriele Fischer. (2005) Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction 100:8, 1101-1109
CrossRef122
Hendree E. Jones, Conrad J. Wong, Michelle Tuten, Maxine L. Stitzer. (2005) Reinforcement-based therapy: 12-month evaluation of an outpatient drug-free treatment for heroin abusers. Drug and Alcohol Dependence 79:2, 119-128
CrossRef123
Alison Oliveto, James Poling, Kevin A. Sevarino, Kishorchandra R. Gonsai, Elinore F. McCance-Katz, Susan M. Stine, Thomas R. Kosten. (2005) Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug and Alcohol Dependence 79:2, 157-165
CrossRef124
Fabian Termorshuizen, Anneke Krol, Maria Prins, Ronald Geskus, Wim van den Brink, Erik J.C. van Ameijden. (2005) Prediction of relapse to frequent heroin use and the role of methadone prescription: An analysis of the Amsterdam Cohort Study among drug users. Drug and Alcohol Dependence 79:2, 231-240
CrossRef125
Douglas Longshore, Jeffrey Annon, M. Douglas Anglin, Richard A. Rawson. (2005) Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use. Addiction 100:8, 1131-1139
CrossRef126
E. F. McCance-Katz. (2005) Treatment of Opioid Dependence and Coinfection with HIV and Hepatitis C Virus in Opioid- Dependent Patients: The Importance of Drug Interactions between Opioids and Antiretroviral Agents. Clinical Infectious Diseases 41:Supplement 1, S89-S95
CrossRef127
Hendree E. Jones, Rolley E. Johnson, Donald R. Jasinski, Kevin E. O’Grady, Christian A. Chisholm, Robin E. Choo, Michael Crocetti, Robert Dudas, Cheryl Harrow, Marilyn A. Huestis, Lauren M. Jansson, Michael Lantz, Barry M. Lester, Lorraine Milio. (2005) Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence 79:1, 1-10
CrossRef128
Michelle R Lofwall, Maxine L Stitzer, George E Bigelow, Eric C Strain. (2005) Comparative Safety and Side Effect Profiles of Buprenorphine and Methadone in the Outpatient Treatment of Opioid Dependence. Addictive Disorders & Their Treatment 4:2, 49-64
CrossRef129
S. Neri, C. M. Bruno, D. Pulvirenti, M. Malaguarnera, C. Italiano, B. Mauceri, G. Abate, D. Cilio, S. Calvagno, A. Tsami, L. Ignaccolo, D. Interlandi, L. Prestianni, M. Ricchena, R. Noto. (2005) Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology 179:3, 700-704
CrossRef130
Lisa A. Marsch, Warren K. Bickel, Gary J. Badger, Eric A. Jacobs. (2005) Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug and Alcohol Dependence 77:2, 195-204
CrossRef131
Anthony H Harris, Elena Gospodarevskaya, Alison J Ritter. (2005) A Randomised Trial of the Cost Effectiveness of Buprenorphine as an Alternative to Methadone Maintenance Treatment for Heroin Dependence in a Primary Care Setting. PharmacoEconomics 23:1, 77-91
CrossRef132
Evan Wood, Kathy Li, Anita Palepu, David C. Marsh, Martin T. Schechter, Robert S. Hogg, Julio S. G. Montaner, Thomas Kerr. (2005) Sociodemographic Disparities in Access to Addiction Treatment a Among a Cohort of Vancouver Injection Drug Users. Substance Use & Misuse 40:8, 1153-1167
CrossRef133
Joy C. Draper, Elinore F. McCance-Katz. (2005) Medical Illness and Comorbidities in Drug Users: Implications for Addiction Pharmacotherapy Treatment. Substance Use & Misuse 40:13-14, 1899-1921
CrossRef134
Evan D Kharasch, Dale Whittington, Christine Hoffer, Kevin Krudys, Keith Craig, Paolo Vicini, Pam Sheffels, Bojan Lalovic. (2005) Paradoxical Role of Cytochrome P450 3A in the Bioactivation and Clinical Effects of Levo-??-Acetylmethadol. Clinical Pharmacokinetics 44:7, 731-751
CrossRef135
Alexander Elkader, Beth Sproule. (2005) Buprenorphine. Clinical Pharmacokinetics 44:7, 661-680
CrossRef136
Ravindra V. Rao, Anju Dhawan, Neerja Sapra. (2005) Opioid maintenance therapy with slow release oral morphine: Experience from India. Journal of Substance Use 10:5, 259-261
CrossRef137
Lisa A. Marsch, Mary Ann Chutuape Stephens, Timothy Mudric, Eric C. Strain, George E. Bigelow, Rolley E. Johnson. (2005) Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.. Experimental and Clinical Psychopharmacology 13:4, 293-302
CrossRef138
M SOFUOGLU, T KOSTEN. (2004) Pharmacologic management of relapse prevention in addictive disorders. Psychiatric Clinics of North America 27:4, 627-648
CrossRef139
Jaroon Jittiwutikarn, Robert Ali, Jason M. White, Felix Bochner, Andrew A. Somogyi, David J. R. Foster. (2004) Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. British Journal of Clinical Pharmacology 58:5, 536-541
CrossRef140
Thomas R. Kosten, Therese A. Kosten. (2004) New medication strategies for comorbid substance use and bipolar affective disorders. Biological Psychiatry 56:10, 771-777
CrossRef141
NANCY M. PETRY. (2004) Depot formulations: will pharmacological advances improve treatment options and outcomes for substance abusers?. Addiction 99:11, 1475-1476
CrossRef142
Thomas Kerr, Alex Wodak, Richard Elliott, Julio S Montaner, Evan Wood. (2004) Opioid substitution and HIV/AIDS treatment and prevention. The Lancet 364:9449, 1918-1919
CrossRef143
Fergus D. Law, Judy S. Myles, Mark R. C. Daglish, David J. Nutt. (2004) The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatrica 16:5, 246-274
CrossRef144
Annie Umbricht, Marilyn A. Huestis, Edward J. Cone, Kenzie L. Preston. (2004) Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers. Journal of Clinical Psychopharmacology 24:5, 479-487
CrossRef145
David A.L. Newcombe, Felix Bochner, Jason M. White, Andrew A. Somogyi. (2004) Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. Drug and Alcohol Dependence 76:1, 63-72
CrossRef146
Hendr??e E Jones, Rolley E Johnson, George E Bigelow, Eric C Strain. (2004) Differences at Treatment Entry Between Opioid-Dependent and Cocaine-Dependent Males and Females. Addictive Disorders & Their Treatment 3:3, 110-121
CrossRef147
David A. Fiellin, Herbert Kleber, Jeanne G. Trumble-Hejduk, A. Thomas McLellan, Thomas R. Kosten. (2004) Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment 27:2, 153-159
CrossRef148
Timothy B. Mitchell, Jason M. White, Andrew A. Somogyi, Felix Bochner. (2004) Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 99:8, 940-945
CrossRef149
S. Pirnay, S. W. Borron, C. P. Giudicelli, J. Tourneau, F. J. Baud, I. Ricordel. (2004) A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 99:8, 978-988
CrossRef150
Stephane Pirnay, Stephane Bouchonnet, Françoise Hervé, Danielle Libong, Nathalie Milan, Philippe d’Athis, Frédéric Baud, Ivan Ricordel. (2004) Development and validation of a gas chromatography–mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. Journal of Chromatography B 807:2, 335-342
CrossRef151
C.B. Eap, G. Bouchoux, N. Scherbaum, M. Gastpar, K. Powell Golay, P. Baumann. (2004) Determination of human plasma levels of levo-α-acetylmethadol and its metabolites by gas chromatography–mass spectrometry. Journal of Chromatography B 805:1, 141-146
CrossRef152
Uwe Verthein, Michael Prinzleve, Georg Farnbacher, Christian Haasen, Michael Krausz. (2004) Treatment of Opiate Addicts With Buprenorphine. Addictive Disorders & Their Treatment 3:2, 58-70
CrossRef153
Evan Wood, Patricia Spittal, Kathy Li, Thomas Kerr, Cari L. Miller, Robert S. Hogg, Julio S. G. Montaner, Martin T. Schechter. (2004) Inability to Access Addiction Treatment and Risk of HIV Infection Among Injection Drug Users. JAIDS Journal of Acquired Immune Deficiency Syndromes 36:2, 750-754
CrossRef154
P Kouya. (2004) Buprenorphine reduces central sensitization after repetitive C-fiber stimulation in rats. Neuroscience Letters 359:1-2, 127-129
CrossRef155
Gerardo Gonzalez, Alison Oliveto, Thomas R Kosten. (2004) Combating opiate dependence: a comparison among the available pharmacological options. Expert Opinion on Pharmacotherapy 5:4, 713-725
CrossRef156
Judith Martin. (2004) Evolving Use of Buprenorphine in the Treatment of Addiction. Journal of Psychoactive Drugs 36:sup2, 129-137
CrossRef157
Sharon K. Schmidt. (2004) Buprenorphine: A New Treatment Adjunct. Journal of Addictions Nursing 15:1, 47-48
CrossRef158
Debra S Harris, John E Mendelson, Emil T Lin, Robert A Upton, Reese T Jones. (2004) Pharmacokinetics and Subjective Effects of Sublingual Buprenorphine, Alone or in Combination with Naloxone. Clinical Pharmacokinetics 43:5, 329-340
CrossRef159
Kenneth Silverman, Elias Robles, Timothy Mudric, George E. Bigelow, Maxine L. Stitzer. (2004) A Randomized Trial of Long-Term Reinforcement of Cocaine Abstinence in Methadone-Maintained Patients Who Inject Drugs.. Journal of Consulting and Clinical Psychology 72:5, 839-854
CrossRef160
S. C. Armstrong, K. L. Cozza. (2004) Buprenorphine: A New Treatment Adjunct. Journal of Addictions Nursing 15:1, 47-48
CrossRef161
Christopher Stock, Jason H. Shum. (2004) Buprenorphine. Journal of Pain and Palliative Care Pharmacotherapy 18:3, 35-54
CrossRef162
Wim van den Brink, Jan M. van Ree. (2003) Pharmacological treatments for heroin and cocaine addiction. European Neuropsychopharmacology 13:6, 476-487
CrossRef163
Barry Stimmel. (2003) Methadone and Affairs of the Heart and of the Brain. Journal of Addictive Diseases 22:3, 1-5
CrossRef164
Marc Galanter, Helen Dermatis, Richard Resnick, Robert Maslansky, Erna Neumann. (2003) Short-Term Buprenorphine Maintenance. Journal of Addictive Diseases 22:3, 39-49
CrossRef165
Alison J. Ritter, Nicholas Lintzeris, Nicolas Clark, Jozica J. Kutin, Gabriele Bammer, Mary Panjari. (2003) A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction 98:11, 1605-1613
CrossRef166
Evan Wood, Julio SG Montaner, David R Bangsberg, Mark W Tyndall, Steffanie A Strathdee, Michael V O'Shaughnessy, Robert S Hogg. (2003) Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS 17:17, 2419-2427
CrossRef167
Anne Guichard, France Lert, Christine Calderon, Hind Gaigi, Olivier Maguet, Jérôme Soletti, Jean-Marc Brodeur, Lucie Richard, Mike Benigeri, Maria-Victoria Zunzunegui. (2003) Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction 98:11, 1585-1597
CrossRef168
Timothy B Mitchell, Jason M White, Andrew A Somogyi, Felix Bochner. (2003) Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug and Alcohol Dependence 72:1, 85-94
CrossRef169
Maria-Patrizia Carrieri, D. Rey, A. Loundou, G. Lepeu, A. Sobel, Y. Obadia. (2003) Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug and Alcohol Dependence 72:1, 13-21
CrossRef170
Fudala, Paul J., Bridge, T. Peter, Herbert, Susan, Williford, William O., Chiang, C. Nora, Jones, Karen, Collins, Joseph, Raisch, Dennis, Casadonte, Paul, Goldsmith, R. Jeffrey, Ling, Walter, Malkerneker, Usha, McNicholas, Laura, Renner, John, Stine, Susan, Tusel, Donald, . (2003) Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone. New England Journal of Medicine 349:10, 949-958
Full Text171
Camí, Jordi, Farré, Magí, . (2003) Drug Addiction. New England Journal of Medicine 349:10, 975-986
Full Text172
J. Ahmadi, K. Ahmadi, J. Ohaeri. (2003) Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. European Journal of Clinical Investigation 33:9, 824-829
CrossRef173
Fabrizio Faggiano, Federica Vigna-Taglianti, Elisabetta Versino, Patrizia Lemma, Fabrizio Faggiano. 2003. Methadone maintenance at different dosages for opioid dependence. .
CrossRef174
Mark K. Greenwald, Kory J. Schuh, Susan M. Stine. (2003) Transferring Methadone-maintained Outpatients to the Buprenorphine Sublingual Tablet: A Preliminary Study. The American Journal on Addictions 12:4, 365-374
CrossRef175
Wim van den Brink, Marian Goppel, Jan van Ree. (2003) Current Opinion in Psychiatry 16:3, 297-304
CrossRef176
Wim van den Brink, Marian Goppel, Jan M. van Ree. (2003) Management of opioid dependence. Current Opinion in Psychiatry 16:3, 297-304
CrossRef177
Olga V Lopatko, Jason M White, Alice Huber, Walter Ling. (2003) Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. Drug and Alcohol Dependence 69:3, 317-322
CrossRef178
Richard P. Mattick, Robert Ali, Jason M. White, Susannah O'Brien, Seija Wolk, Cath Danz. (2003) Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 98:4, 441-452
CrossRef179
Johan Kakko, Kerstin Dybrandt Svanborg, Mary Jeanne Kreek, Markus Heilig. (2003) 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. The Lancet 361:9358, 662-668
CrossRef180
Irene Kuo, Joseph Brady, Carol Butler, Robert Schwartz, Robert Brooner, David Vlahov, Steffanie A Strathdee. (2003) Feasibility of referring drug users from a needle exchange program into an addiction treatment program: Experience with a mobile treatment van and LAAM maintenance. Journal of Substance Abuse Treatment 24:1, 67-74
CrossRef181
Wei Huang, Paul A. Bemis, Matthew H. Slawson, David E. Moody. (2003) Determination ofl-?-acetylmethadol (LAAM), norLAAM, and dinorLAAM in clinical andIn Vitro samples using liquid chromatography with electrospray ionization and tandem mass spectrometry. Journal of Pharmaceutical Sciences 92:1, 10-20
CrossRef182
Jami L Rothenberg, Maria A Sullivan, Sarah H Church, Angela Seracini, Eric Collins, Herbert D Kleber, Edward V Nunes. (2002) Behavioral naltrexone therapy. Journal of Substance Abuse Treatment 23:4, 351-360
CrossRef183
M.CATERINA GRASSI, M.LUISA BENCETTI, ALESSIO MARIA CARICATI, PAOLO NENCINI. (2002) PREDICTIVE FACTORS OF PERSISTING ILLICIT DRUG USE IN HOSPITALIZED HEROIN ADDICTS. Pharmacological Research 46:6, 539-544
CrossRef184
Susan E. Robinson. (2002) Buprenorphine: An Analgesic with an Expanding Role in the Treatment of Opioid Addiction. CNS Drug Reviews 8:4, 377-390
CrossRef185
P. N. Gueye, B. Megarbane, S. W. Borron, F. Adnet, M. Galliot-Guilley, I. Ricordel, J. Tourneau, D. Goldgran-Toledano, F. J. Baud. (2002) Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. Addiction 97:10, 1295-1304
CrossRef186
Harry W. Daniell. (2002) Narcotic-Induced Hypogonadism During Therapy for Heroin Addiction. Journal of Addictive Diseases 21:4, 47-53
CrossRef187
Fiellin, David A., O'Connor, Patrick G., . (2002) Office-Based Treatment of Opioid-Dependent Patients. New England Journal of Medicine 347:11, 817-823
Full Text188
Philip S. Mehler. (2002) Treating Opioid Dependence: Growing Implications for Primary Care. Primary Care Case Reviews 5:3, 132-139
CrossRef189
Mary Jeanne Kreek, Frank J. Vocci. (2002) History and current status of opioid maintenance treatments: blending conference session. Journal of Substance Abuse Treatment 23:2, 93-105
CrossRef190
Walter Ling, David Smith. (2002) Buprenorphine: blending practice and research. Journal of Substance Abuse Treatment 23:2, 87-92
CrossRef191
Poli Francois Kouya, Jing-Xia Hao, Xiao-Jun Xu. (2002) Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. European Journal of Pharmacology 450:1, 49-53
CrossRef192
Joseph O. Merrill. (2002) Policy Progress for Physician Treatment of Opiate Addiction. Journal of General Internal Medicine 17:5, 361-368
CrossRef193
Jason M White, Cath Danz, Joanne Kneebone, Sophie F La Vincente, David A.L Newcombe, Robert L Ali. (2002) Relationship between LAAM–methadone preference and treatment outcomes. Drug and Alcohol Dependence 66:3, 295-301
CrossRef194
Nicolas C Clark, Nicholas Lintzeris, Alan Gijsbers, Greg Whelan, Adrian Dunlop, Alison Ritter, Walter W Ling, Nicolas C Clark. 2002. LAAM maintenance vs methadone maintenance for heroin dependence. .
CrossRef195
Magı́ Farré, Anna Mas, Marta Torrens, Vı́ctor Moreno, Jordi Camı́. (2002) Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug and Alcohol Dependence 65:3, 283-290
CrossRef196
Cherokee Layson-Wolf, Jean-Venable Goode, Ralph E. Small. (2002) Clinical Use of Methadone. Journal of Pain and Palliative Care Pharmacotherapy 16:1, 29-59
CrossRef197
Chin B. Eap, Thierry Buclin, Pierre Baumann. (2002) Interindividual Variability of the Clinical Pharmacokinetics of Methadone. Clinical Pharmacokinetics 41:14, 1153-1193
CrossRef198
Gerardo Gonzalez, Alison Oliveto, Thomas R. Kosten. (2002) Treatment of Heroin (Diamorphine) Addiction. Drugs 62:9, 1331-1343
CrossRef199
Isabelle M Maisonneuve, Laurie M Warner, Stanley D Glick. (2001) Biphasic dose-related effects of morphine on dopamine release. Drug and Alcohol Dependence 65:1, 55-63
CrossRef200
David A Wasserman, Anita L Stewart, Kevin L Delucchi. (2001) Social support and abstinence from opiates and cocaine during opioid maintenance treatment. Drug and Alcohol Dependence 65:1, 65-75
CrossRef201
Anthony L. Vaccarino, Abba J. Kastin. (2001) Endogenous opiates: 2000. Peptides 22:12, 2257-2328
CrossRef202
Anke Gross, Eric A. Jacobs, Nancy M. Petry, Gary J. Badger, Warren K. Bickel. (2001) Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days. Drug and Alcohol Dependence 64:1, 111-116
CrossRef203
Michael I. Fingerhood, Michele R. Thompson, Donald R. Jasinski. (2001) A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Substance Abuse 22:3, 193-199
CrossRef204
(2001) Treating Opioid Dependence. New England Journal of Medicine 344:7, 530-531
Full Text205
CHRISTOPHER J. WELSH, JOSEPH LIBERTO. (2001) The Use of Medication for Relapse Prevention in Substance Dependence Disorders. Journal of Psychiatric Practice 7:1, 15-31
CrossRef206
O'Connor, Patrick G., . (2000) Treating Opioid Dependence — New Data and New Opportunities. New England Journal of Medicine 343:18, 1332-1334
Full Text207
&NA;. (2000) New treatment options for opioid dependence. Inpharma Weekly &NA;:1263, 10
CrossRef
